IL-6 is required for glioma development in a mouse model. (Q47817716)

5 February 2018

title

IL-6 is required for glioma development in a mouse model. (English)

1 reference

5 February 2018

author

Manfred Kopf

4

1 reference

5 February 2018

Adriano Aguzzi

7

1 reference

5 February 2018

author name string

Jakob Weissenberger

1

1 reference

5 February 2018

Sébastien Loeffler

2

1 reference

5 February 2018

Andreas Kappeler

3

1 reference

5 February 2018

Anton Lukes

5

1 reference

5 February 2018

Tatiana A Afanasieva

6

1 reference

5 February 2018

Joachim Weis

8

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 April 2004

1 reference

5 February 2018

published in

Oncogene

1 reference

5 February 2018

volume

23

1 reference

5 February 2018

page(s)

3308-3316

1 reference

5 February 2018

issue

19

1 reference

5 February 2018

https://scigraph.springernature.com/pub.10.1038/sj.onc.1207455

exact match

0 references

cites work

Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

A possible growth factor role of IL-6 in neuroectodermal tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

Rac1 mediates STAT3 activation by autocrine IL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

Rac1 activity is required for the activation of hypoxia-inducible factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

Gliomagenesis: genetic alterations and mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

Interleukin-6 overexpression as a marker of malignancy in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

IL-6 gene amplification and expression in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Interleukin-6-mediated autocrine growth promotion in human glioblastoma multiforme cell line U87MG.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Activation of the JAK/STAT pathway following transient focal cerebral ischemia: signaling through Jak1 and Stat3 in astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Impaired neuroglial activation in interleukin-6 deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Directly linked soluble IL-6 receptor-IL-6 fusion protein induces astrocyte differentiation from neuroepithelial cells via activation of STAT3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207455

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1207455

1 reference

5 February 2018

Dimensions Publication ID

0 references

1 reference

5 February 2018